Regular vs ad-lib albuterol for patients hospitalized with acute asthma

Chest

Volumn 128, Issue 3, 2005, Pages 1115-1120

  Chandra, Alpana ^a   Shim, Chang ^a   Cohen, Hillel W ^b   Chung, Virginia ^a   Maggiore, Diane ^a   Mani, Kartik ^b   Dhuper, Sunil ^a  

^a JACOBI MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Adrenergic agonists; Asthma; Bronchodilator; Drug therapy; Randomized control trial

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; SALBUTAMOL; SHORT ACTING DRUG;

ACUTE DISEASE; ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MALE; METERED DOSE INHALER; NEBULIZATION; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; UNITED STATES;

EID: 24944466409     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.3.1115     Document Type: Article

References (29)

1. Neri M, Spanevello A. Chronic bronchial asthma from challenge to treatment: epidemiology and social impact. Thorax 2000; 55(Suppl2):S57-S58
2. FitzGerald JM, Macklem P. Fatal asthma. Annu Rev Med 1996; 47:161-168
3. Weiss KB, Gergen PJ, Wagener DK. Breathing better or wheezing worse? The changing epidemiology of asthma morbidity and mortality. Annu Rev Public Health 1993; 14:491-513
4. The British guidelines on asthma management 1995 review and position statement. Thorax 1997; 52:1S-120S
5. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, 1997; 46-47
6. Nebulizer therapy: guidelines. British Thoracic Society Nebulizer Project Group. Thorax 1997; 52(Suppl 2):S4-S24
7. Lin RY, Sauter D, Newman T, et al. Continuous versus intermittent albuterol nebulization in the treatment of acute asthma. Ann Emerg Med 1993; 22:1847-1853
8. Rudnitsky GS, Eberlein RS, Schoffstall JM, et al. Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department. Ann Emerg Med 1993; 22:1842-1846
9. Bjornsdottir US, Cypcar DM. Asthma: an inflammatory mediator soup. Allergy 1999; 54(Suppl 49):55-61
10. Horwitz RJ, Busse WW. Inflammation and asthma. Clin Chest Med 1995; 16:583-602
11. Wilson JW. What causes airway remodeling in asthma? Clin Exp Allergy 1998; 28:534-536
12. Lipworth BJ, Clark RA, Dhillon DP, et al. β-Adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma. Br J Clin Pharmacol 1988; 26:527-533
13. Choo-Kang YF, Simpson WT, Grant IW. Controlled comparison of the bronchodilator effects of three β-adrenergic stimulant drugs administered by inhalation to patients with asthma. BMJ 1969; 2:287-289
14. 2-agonists: inhibition of TNF-α release from human mast cells. J Allergy Clin Immunol 1997; 100:825-831
15. Strube G, Rudolf M. For and against: should steroids be the first line treatment for asthma? BMJ 2000; 320:47-49
16. Sears MR, Taylor DR, Print CG, et al. Regular inhaled β-agonist treatment in bronchial asthma. Lancet 1990; 336:1391-1396
17. Hancox RJ, Cowan JO, Flannery EM, et al. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled β-agonist treatment. Respir Med 2000; 94:767-771
18. Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326:501-506
19. Castro M, Schechtman KB, Halstead J, et al. Risk factors for asthma morbidity and mortality in a large metropolitan city. J Asthma 2001; 38:625-635
20. Bradding P, Rushby I, Scullion J, et al. As-required versus regular nebulized salbutamol for the treatment of acute severe asthma. Eur Respir J 1999; 13:290-294
21. Claudio L, Tulton L, Doucette J, et al. Socioeconomic factors and asthma hospitalization rates in New York City. J Asthma 1999; 36:343-350
22. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the β(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162:75-80
23. Taylor DR, Drazen JM, Herbison GP, et al. Asthma exacerbations during long term β-agonist use: influence of β(2)-adrenoceptor polymorphism. Thorax 2000; 55:762-767
24. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364:1505-1512
25. 2-Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am J Respir Grit Care Med 1998; 158:787-791
26. Wark PA, Simpson JL, Hensley MJ, et ai. Safety of sputum induction with isotonic saline in adults with acute severe asthma. Clin Exp Allergy 2001; 31:1745-1753
27. Dautzenberg B. Prevention of nosocomial infection during nebulization and spirometry [in French]. Rev Pneumol Clin 2001; 57:91-98
28. Stanford R, McLaughlin T, Okamoto LJ. The cost of asthma in the emergency department and hospital. Am J Respir Crit Care Med 1999; 160:211-215
29. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992; 326:862-866